Clinical Trial Update: A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating Apremilast for active Behçet's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Behçet's Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2019-09-11